MONTREAL -- 11/19/07 -- TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in developing products for respiratory disorders, today announced that the first patients have been dosed in a Phase 2 trial, designed to evaluate the safety, tolerability and proof-of-concept of inhaled TPI 1020 in patients suffering from chronic obstructive pulmonary disease (COPD). TPI 1020 is a novel, anti-inflammatory respiratory drug licensed from NicOx S.A. for respiratory indications.
